A Diagnostic Algorithm for Posterior Fossa Tumors in Children: A Validation Study


AJNR Am J Neuroradiol  published online 4 March 2021
http://www.ajnr.org/content/early/2021/03/04/ajnr.A7057
A Diagnostic Algorithm for Posterior Fossa Tumors in Children: A Validation Study


ABSTRACT

BACKGROUND AND PURPOSE: Primary posterior fossa tumors comprise a large group of neoplasias with variable aggressiveness and short and long-term outcomes. This study aimed to validate the clinical usefulness of a radiologic decision flow chart based on previously published neuroradiologic knowledge for the diagnosis of posterior fossa tumors in children.

MATERIALS AND METHODS: A retrospective study was conducted (from January 2013 to October 2019) at 2 pediatric referral centers, Children's Hospital of Philadelphia, United States, and Great Ormond Street Hospital, United Kingdom. Inclusion criteria were younger than 18 years of age and histologically and molecularly confirmed posterior fossa tumors. Subjects with no available preoperative MR imaging and tumors located primarily in the brain stem were excluded. Imaging characteristics of the tumors were evaluated following a predefined, step-by-step flow chart. Agreement between readers was tested with the Cohen κ, and each diagnosis was analyzed for accuracy.

RESULTS: A total of 148 cases were included, with a median age of 3.4 years (interquartile range, 2.1–6.1 years), and a male/female ratio of 1.24. The predefined flow chart facilitated identification of pilocytic astrocytoma, ependymoma, and medulloblastoma sonic hedgehog tumors with high sensitivity and specificity. On the basis of the results, the flow chart was adjusted so that it would also be able to better discriminate atypical teratoid/rhabdoid tumors and medulloblastoma groups 3 or 4 (sensitivity = 75%–79%; specificity = 92%–99%). Moreover, our adjusted flow chart was useful in ruling out ependymoma, pilocytic astrocytomas, and medulloblastoma sonic hedgehog tumors.

CONCLUSIONS: The modified flow chart offers a structured tool to aid in the adjunct diagnosis of pediatric posterior fossa tumors. Our results also establish a useful starting point for prospective clinical studies and for the development of automated algorithms, which may provide precise and adequate diagnostic tools for these tumors in clinical practice.

ABBREVIATIONS: AT/RT = atypical teratoid/rhabdoid tumor; LR = likelihood ratio; NPV = negative predictive value; PA = pilocytic astrocytoma; PPV = positive predictive value; WNT = wingless; SHH = sonic hedgehog

In the past 10 years, there has been an exponential increase in knowledge of the molecular characteristics of pediatric brain tumors, which was only partially incorporated in the 2016 World Health Organization Classification of Tumors of the Central Nervous System. The main update in the 2016 Classification was the introduction of the molecular profile of a tumor as an important factor for predicting different biologic behaviors of entities which, on histology, look very similar or even indistinguishable. A typical example is the 4 main groups of medulloblastoma: wingless (WNT), sonic hedgehog (SHH) with or without the p53 mutation, group 3, and group 4. Although they may appear similar on microscopy, these categories have distinct molecular profiles, epidemiology, prognosis, and embryologic origin.

Subsequent to the publication of the 2016 World Health Organization Classification, further studies have identified even more molecular subgroups of medulloblastoma with possible prognostic implications and also at least 3 new molecular subgroups of atypical teratoid/rhabdoid tumor (AT/RT) and several subgroups of ependymoma. MR imaging shows promise as a technique for differentiating histologic tumors and their molecular subgroups. This capability relies on not only various imaging characteristics but also the location and spatial extension of the tumor, evident on MR imaging, which can be traced to the embryologic origin of the neoplastic cells.
One approach to the challenge of identifying imaging characteristics of different tumors in children is to use artificial intelligence. Yet despite this exciting innovation, correctly identifying the location of the mass and its possible use as an element for differential diagnosis still requires the expertise of an experienced radiologist. Previously, D’Arco et al. proposed a flow chart (Fig 1) for the differential diagnosis of posterior fossa tumors in children based on epidemiologic, imaging signal, and location characteristics of the neoplasm. The aims of the current study were the following: 1) to validate, in a retrospective, large cohort of posterior fossa tumors from 2 separate pediatric tertiary centers, the diagnostic accuracy of that flow chart, which visually represents the neuroradiologist’s mental process in making a diagnosis of posterior fossa tumors in children, 2) to describe particular types of posterior fossa lesions that are not correctly diagnosed by the initial flow chart, and 3) to provide an improved, clinically accessible flow chart based on the results.

**MATERIALS AND METHODS**

**Setting and Subjects**

A retrospective, cross-sectional study from 2 large tertiary referral pediatric hospitals in 2 countries (Children’s Hospital of Philadelphia, United States, and Great Ormond Street Hospital, London, United Kingdom) was performed on the basis of patient records spanning January 2013 to October 2019 in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement.2 This study was conducted under 2 research protocols (IRB No. 18-015588 and CA Reg No. 2504), approved by the respective institutional review boards at each center.

Subjects were identified by electronic search of brain MR imaging reports and the electronic health record systems. The following terms/diagnoses were used for the search: “brain tumor,” “posterior fossa tumor,” “brain neoplasia,” “posterior fossa neoplasia,” “cerebellar tumor,” “cerebellar neoplasm,” “medulloblastoma,” “AT/RT,” “atypical teratoid/rhabdoid tumor,” “ependymoma,” “pilocytic astrocytoma.” Results were screened, and subjects younger than 18 years of age with a histologically and genetically confirmed diagnosis of posterior fossa tumor, according to the 2016 World Health Organization classification, were selected.2 Subjects with no available preoperative MR imaging study, those with low-quality MR imaging studies, and those without diffusion imaging on their MR imaging study were excluded. Subjects with tumors located primarily in the brain stem were also excluded.

**Variables**

Age at first MR imaging (before histologic/pathologic confirmation of the tumor), sex, and histologic and genetic/molecular results
were obtained from the electronic medical records. Two experienced pediatric neuroradiologists independently reviewed these initial MR imaging studies at each institution (C.A.P.F.A., A.V., F.D., and U.L.), blinded to the final diagnosis. Imaging characteristics were evaluated following a step-by-step numeric flow chart, with a digit assigned to each level and subsequent branch, providing a flow chart and a 3-digit numeric sequence code for each diagnosis end point to be used in the analysis (Fig 1). The flow chart took into account the following: 1) tumor location, 2) ADC map signal intensity in comparison with gray matter, 3) internal architecture, 4) contrast enhancement, and 5) the patient’s age. The flow chart was designed before the initiation of the study; it was based on a review on the topic by D’Arco et al.1 Before starting the blinded analysis of the cohort, one of the readers (C.A.P.F.A.) performed a pilot evaluation using the first 8 cases from each institution (16/148; 10.8%) to confirm the applicability of the flow chart multiple weeks before the formal evaluation.

Statistical Analysis
Visual inspection of the histogram showed non-normal distribution, which was confirmed with the Shapiro-Wilk test (P < .001) for all numeric variables. Categoric variables are described with percentage and frequency, and numeric variables, with median and interquartile range. Statistical analysis was performed using R statistical and computing software, Version 3.5.3 for Windows (http://www.r-project.org/). Diagnostic accuracy of the flow chart was verified through a 2 × 2 contingency table and calculation of sensitivity, specificity, positive predictive values (PPV), and negative predictive value (NPV). To estimate accuracy and effect size, we estimated 95% CIs for sensitivity, specificity, PPV, and NPV. The diagnostic accuracy analysis was performed for each diagnosis, with molecular/histologic diagnosis as the criterion standard comparison. Because flow chart numeric sequences 312 and 311 of the predesigned flow chart would not provide a single unique final tumor molecular diagnosis, we later adjusted the sequences according to the most prevalent diagnosis. The modified flow chart reflects these adjustments. Last, we recalculated diagnostic accuracy tests considering both 311 and 312 as a single diagnosis as group 3 or 4 (3 confirmed as group 3, eight confirmed as group 4, and 15, or 4 or 5 confirmed as group 3, eight confirmed as group 4, and 15, as group 3 or 4). The remaining cases under sequence 31 did not otherwise specified, 1 hemangioblastoma, 2 gangliogliomas, 1 desmoplastic medulloblastoma all subgroups, 26/35 (74%) were confirmed as group 3 or 4 (3 confirmed as group 3, eight confirmed as group 4, and 15, as group 3 or 4). The remaining cases under sequence 312 were 3/35 (9%) SHH, 5/35 (14%) WNT, and 1/35 (3%) AT/RT. Figure 3 shows the diagnostic accuracy of sequence 312 to identify medulloblastoma SHH, WNT, and group 3 or 4. For this sequence, the NPV and specificity were higher than the PPV and sensitivity for all other sequences. Table 2 shows the LR analysis for cases of AT/RT improved when combining sequences 311 and 411 as AT/RTs. As can be appreciated in Fig 2 and Table 1, diagnostic accuracy for cases of AT/RT improved when combining sequences 311 and 411. Of the 35 cases under sequence 312 (medulloblastoma all subgroups), 26/35 (74%) were confirmed as group 3 or 4 (3 confirmed as group 3, eight confirmed as group 4, and 15, as group 3 or 4). The remaining cases under sequence 312 were 3/35 (9%) SHH, 5/35 (14%) WNT, and 1/35 (3%) AT/RT. Figure 3 shows the diagnostic accuracy of sequence 312 to identify medulloblastoma SHH, WNT, and group 3 or 4. For this sequence, the NPV and specificity were higher than the PPV and sensitivity for all other sequences. Table 2 shows the LR analysis per diagnosis and the recommended sequences for the diagnosis. After our analysis and on the basis of Table 1 results, we modified the predesigned flow chart with more precise categorization of the types of tumor. We recommend this new flow chart (Fig 4) for the diagnosis of posterior fossa tumors in children.

Some examples of differentiating posterior fossa tumors from our cohort, diagnosed on the basis of the new flow chart here presented, can be seen in Figs 5 and 6.

RESULTS
Histologic Diagnosis and Demographics
One hundred forty-eight subjects were included. The median age at MR imaging was 3.4 years, (interquartile range = 2.1–6.1 years), and the male/female ratio was 1.24. Fifty-four (36.5%) patients had a histologic diagnosis of medulloblastoma, 56 (37.5%) had pilocytic astrocytoma (PA), 12 (8.1%) had AT/RT, and 19 (12.8%) had ependymoma. Medulloblastomas were also subclassified according to molecular subtypes including 14/54 (26%) SHH, 7/54 (13%) WNT, 5/54 (9%) group 3; 9/54 (17%) group 4; and 19/54 (35%) group 3 or 4 (separation of groups 3 and 4 was not always easily possible). Seven cases (5%) had a diagnosis of other tumors not covered by the flow chart (2 low-grade diffuse astrocytomas not otherwise specified, 1 hemangioblastoma, 2 gangliogliomas, 1 case of Langerhans cell histiocytosis, and 1 meningioma).

DISCUSSION
The 2016 introduction of the new classification of brain tumors based on histologic and molecular characteristics dramatically changed the management of pediatric brain tumors.1,2,14,15 Tumors with similar histologic appearance being related to
completely different cellular populations with different molecular profiles and different embryologic origins implies that they develop along different cellular paths. Thus, tumors that were previously considered as a single group can now be differentiated on imaging by location, age, and/or the patient’s signal characteristics, resulting in a more accurate prognosis.16-18

In light of the crucial role of molecular profiling in tumor diagnosis and management, we found that the predesigned flowchart was very useful for categorizing and better understanding pediatric brain tumors. The importance of molecular profiling in the pediatric neuro-oncology clinical practice was first studied in medulloblastomas but is now recognized for ependymomas, low-grade astrocytomas, AT/RTs, and all previously classified primitive neuroectodermal tumors.6,18-22

Yet, since the 2016 classification update, several newly identified radiologic markers have been proposed as surrogates for the molecular diagnosis. The role of these radiologic markers may be limited by the constant evolution of the molecular characterization of brain tumors.8,11 However, we believe that a standardized method of evaluating images, such as the proposed flowchart, may facilitate increased diagnostic accuracy.

The initial predesigned diagnostic flowchart has proved reliable and consistently accurate in this validation study, with an almost perfect agreement between 2 blinded neuroradiologists at 2 different institutions. Our results showed high coefficients of specificity and NPV for all diagnoses included in the predesigned flowchart. Sensitivity coefficients were high (>87%) for diagnosing pilocytic astrocytoma and ependymomas, the 2 most common diagnoses in

<table>
<thead>
<tr>
<th>Diagnosis Equivalent</th>
<th>Flowchart Sequence</th>
<th>Sensitivity (%)</th>
<th>Specificity (%)</th>
<th>PPV (%)</th>
<th>NPV (%)</th>
<th>Accuracy (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ependymoma</td>
<td>323/423</td>
<td>89 (67–99)</td>
<td>95 (89–98)</td>
<td>71 (49–87)</td>
<td>98 (94–100)</td>
<td>94 (89–97)</td>
</tr>
<tr>
<td>Pilocytic astrocytoma</td>
<td>123</td>
<td>88 (76–95)</td>
<td>96 (89–99)</td>
<td>92 (82–98)</td>
<td>93 (85–97)</td>
<td>93 (87–96)</td>
</tr>
<tr>
<td>AT/RT</td>
<td>411</td>
<td>50 (21–79)</td>
<td>99 (96–100)</td>
<td>86 (42–100)</td>
<td>96 (91–98)</td>
<td>99 (96–100)</td>
</tr>
<tr>
<td>AT/RT</td>
<td>411/311</td>
<td>75 (43–95)</td>
<td>98 (94–100)</td>
<td>75 (43–95)</td>
<td>98 (94–100)</td>
<td>91 (96–98)</td>
</tr>
<tr>
<td>Medulloblastoma SHH</td>
<td>111/112/313</td>
<td>71 (42–92)</td>
<td>93 (88–97)</td>
<td>53 (29–76)</td>
<td>97 (92–99)</td>
<td>72 (64–79)</td>
</tr>
<tr>
<td>Medulloblastoma WNT</td>
<td>412</td>
<td>14 (0–58)</td>
<td>97 (93–99)</td>
<td>20 (1–72)</td>
<td>96 (91–98)</td>
<td>88 (93–97)</td>
</tr>
</tbody>
</table>
our cohort. Moreover, PA and ependymoma tumors had the smallest 95% CIs, suggesting reliability in the diagnosis of these 2 types of tumors. This was especially true for PA, in which the lower 95% CI limit for sensitivity was 76%, and for PPV, it was 82%.

After analyzing results from the initial flow chart created on the basis of more recently published literature, we modified it to improve diagnostic accuracy. Our modifications (see Figs 1 and 4 for comparison) successfully improved the sensitivity coefficient for identification of AT/RTs to 75%, but the confidence interval remained wide. The second modification to flow chart sequence 312 made possible the identification of most cases of medulloblastoma group 3 or 4, with fair-to-good sensitivity (61%–91%) and PPV (57%–88%) and good-to-excellent specificity (86%–96%) and NPV (88%–97%). The modified flow chart (Fig 4) proved to be more clinically relevant. The modified flow chart proved capable of discriminating AT/RTs, ependymomas, medulloblastomas SHH, medulloblastoma groups 3 and 4, and PA, which together constitute 90.5% of tumors in our cohort. Clinically, the flow chart demonstrates great performance in ruling out group 3 or 4 medulloblastomas, PAs, and ependymomas and ruling in AT/RTs.

However, when it came to correctly identifying WNT medulloblastoma (numeric sequence 412, Fig 2), diagnostic accuracy was poor. In the predesigned flow chart, the authors designated a tumor in the pontocerebellar angle/foramen of Luschka with high cellularity (ie, low ADC) and patient age older than 3 years as suggestive of WNT. The rationale was that the cellular path of embryologic precursors, which can transform into neoplastic WNT cells, arises from the fourth ventricle down and laterally into the foramen of Luschka. Therefore, susceptibility to WNT medulloblastoma was low, and identification was not possible in the predesigned flow chart.
Luschka. The only other tumor with striking diffusion restriction in the Luschka area is AT/RT, but this is typical of younger children. These results can be explained by several factors: the small number of WNT tumors present in our series (10% of all medulloblastomas), most cases in our series being in the fourth ventricle (which is understandable given that the path of the WNT cells is thought to start from the fourth ventricle), and the presence of anaplastic ependymomas showing diffusion restriction (therefore simulating WNT medulloblastoma on imaging). More recently, a study of a larger cohort of WNT medulloblastomas has shown that they are not as lateralizing as previously reported in smaller cohorts. This study has some limitations, the main one being its retrospective nature. However, we controlled potential biases by doing a blinded review of images by only including cases with images obtained before surgical intervention and creating the baseline flow chart before data collection. Another important limitation is the relatively small number of cases for some types of tumor, which explains the larger confidence intervals for certain tumors. Nevertheless, many pediatric cerebellar tumors are relatively rare, and this is perhaps one of the largest cohorts available in the literature. Moreover, we were able to gather a large enough cohort to allow diagnostic accuracy tests for the most common types of pediatric cerebellar tumors, with reliable results for most diagnoses.

Because this was planned as a validation study, we consider it successful in providing results that show that the modified flow chart can be used, is reliable, and has clinical applicability.

More research is still desired, with a larger consistency analysis evaluating results from multiple blinded readers. A larger prospective study would be needed to evaluate the diagnostic efficacy of the modified flow chart with higher precision. Such a study could provide an initial decision model for potential deep learning studies. Artificial intelligence is already being used to predict the molecular profile of brain tumors, most commonly in adult populations, but with recent important studies emerging in pediatric populations. The main limitation for the application of machine learning in posterior fossa tumors may be the identification of tumor location, because we know that signal characteristics (which reflect at least partially histologic appearances) can be similar for different molecular groups with similar tissue features. Currently, artificial intelligence is not able to differentiate tumors with the necessary level of precision, though this may be possible in the future.

**CONCLUSIONS**

A flow chart for the diagnosis of posterior fossa tumors in children has been validated through a retrospective analysis of 148 patients with confirmed diagnoses. On the basis of analysis of these
hemisphere. Axial T2WI (A) and axial ADC map (B) show SHH medulloblastoma (flow chart 2, number 111) in a typical peripheral location within the cerebellar hemisphere due to its origin from ganglionic cell precursors. Note very low ADC values (ie, diffusion restriction). Axial T2WI (C) and axial ADC map (D) show the typical appearance of a pilocytic astrocytoma (flow chart 2, number 123) originating from the cerebellar hemisphere. Note the typical nodule and appearance of cysts and much higher ADC values in comparison with the medulloblastoma.

FIG 5. Differential diagnoses in cases of posterior fossa tumors originating from the cerebellar hemisphere. Axial T2WI (A) and axial ADC map (B) show SHH medulloblastoma (flow chart 2, number 111) in a typical peripheral location within the cerebellar hemisphere due to its origin from ganglionic cell precursors. Note very low ADC values (ie, diffusion restriction). Axial T2WI (C) and axial ADC map (D) show the typical appearance of a pilocytic astrocytoma (flow chart 2, number 123) originating from the cerebellar hemisphere. Note the typical nodule and appearance of cysts and much higher ADC values in comparison with the medulloblastoma.

FIG 6. Differential diagnoses in posterior fossa tumors involving the foramen of Luschka and cerebellopontine angle. Axial T2WI (A) and ADC map (B) show SHH medulloblastoma (flow chart 2, number 111) in a typical peripheral location within the cerebellar hemisphere due to its origin from ganglionic cell precursors. Note very low ADC values (ie, diffusion restriction). Axial T2WI (C) and axial ADC maps (D) in a 2-year-old boy with a AT/RT (new flow chart number 411). Note the presence of internal vessels (arrow) and intermediate ADC values. Axial T2 (C) and ADC maps (D) in a 2-year-old boy with a AT/RT (new flow chart number 411). Note very low values of ADC, suggesting an embryonal tumor and peripheral cysts.

results, the predesigned flow chart was accurate in identifying most diagnoses, and with our subsequent modifications, the overall accuracy improved. The modified flow chart showed a good likelihood ratio for most of the histologic and molecular groups of tumors. Furthermore, it may offer an important starting point for prospective analysis using machine learning techniques. As new molecular subgroups emerge in the classification of pediatric brain tumors, there is the potential for further modifications to the flow chart to aid in diagnosis.

Disclosures: Ulrike Lölbel—UNRELATED: Employment: Great Ormond Street Hospital; Travel/ Accommodations/Meeting Expenses Unrelated to Activities Listed; European Course in Pediatric Neuroradiology, money paid to individual author. Juan S. Martin-Saavedra—UNRELATED: Employment: The Children’s Hospital of Philadelphia, Comments: This project was done while I was working as a postdoctoral research fellow. Sebastian S. Toescu—RELATED: Grant: Great Ormond Street Hospital Children’s Charity, Comments: I am funded by the Great Ormond Street Hospital Children’s Charity and am an Honorary Research Fellow of the Royal College of Surgeons of England. All research at Great Ormond Street Hospital National Health Service Foundation Trust and the University College London Great Ormond Street Institute of Child Health is made possible by the National Institute of Health Research. Great Ormond Street Hospital Biomedical Research Center.* Miriam H. Tsunemi—UNRELATED: Employment: Medical School of Botucatu-São Paulo State University, Kshitij Mankad—UNRELATED: Employment: Great Ormond Street Hospital, Comments: This is my regular place of work. I am salaried; Expert Testimony: medicolegal work. Comments: I offer expert testimony for cases on an ad hoc basis; Payment for Lectures Including Service on Speakers Bureau: honorarium received from Siemens and Novartis for lecturing. Thomas S. Jacques—UNRELATED: Board Membership: Repath Ltd and Neuropath Ltd, Comments: I am a director of Repath Ltd and Neuropath Ltd; Employment: Repath Ltd, Neuropath Ltd, Comments: I am a director of Repath Ltd and Neuropath Ltd; Expert Testimony: I undertake expert witness work for Her Majesty’s Courts; Grants/Grants Pending: The Brain Tumor Charity, Children with Cancer UK, Great Ormond Street Hospital Children’s Charity, Olivia Houdson Cancer Fund, Cancer Research UK, and the National Institute of Health Research; Payment for Lectures Including Service on Speakers Bureau: Bayer, Comments: I have been invited to give a lecture organized by Bayer; Royalties: Elsevier; Other: Wiley; Comments: I am editor-in-chief of Neuropathology and Applied Neurobiology. *Money paid to the institution.

REFERENCES


